24/7 Wall Street
30 Sept 2026, 13:42 UTC · 1h ago
Verdict
Headline leans bearish. We score MRNA −0.80 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−0.80strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 1 new · 2 priced in
Citigroup downgraded Moderna (MRNA) to Sell from Hold with a price target of $80.
Newpublished Wednesday, Sept 30
So whatThe $80 target represents a ~58% downside from the $191.36 price cited in the text.
More negative than 99% of claims this week
Moderna is expected to release detailed intismeran trial data at the ESMO meeting in late October.
Continue reading
5 related stories
More negative than 84% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inno timing evidence of announcement
So whatA failure to show efficacy beyond melanoma in this October print could trigger a multiple compression toward Citi's target.
More negative than 84% of claims this week
Moderna's stock climbed nearly 590% in 2026 leading into Wednesday's session.
Priced inmulti-year trends
More negative than 68% of claims this week
Which stocks this story touches
More negative than 84% of ticker scores this week
The stock sank 6% following a downgrade to 'Sell' by Citigroup due to overvaluation relative to its pipeline.
Near neutral — 91% of ticker scores this week are stronger
The company is mentioned only as the source of the analyst downgrade.
More positive than 76% of relationship scores this week
[mutual] Moderna and Merck are partnering to develop a personalized cancer vaccine combining Moderna's intismeran with Merck's Keytruda.
More positive than 6% of relationship scores this week
[mutual] The article groups Merck and Pfizer as large pharmaceutical peers.
More positive than 6% of relationship scores this week
[mutual] The article compares Moderna's biotech valuation and volatility against larger pharmaceutical peer Pfizer.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
3h ago
−6.0%
Price agrees with the score
$191.25 vs $203.46 close before publication (Sep 29) · not market-adjusted
MRNA chart →
